Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

Oncotarget

Volumn 3, Issue 7, 2012, Pages 709-722

  Jiao, Yuchen ^a   Killela, Patrick J ^b   Reitman, Zachary J ^b   Rasheed, B Ahmed ^b   Heaphy, Christopher M ^a   de Wilde, Roeland F ^a   Rodriguez, Fausto J ^a   Rosemberg, Sergio ^c   Oba Shinjo, Sueli Mieko ^c   Marie, Suely Kazue Nagahashi ^c   Bettegowda, Chetan ^a   Agrawal, Nishant ^a   Lipp, Eric ^b   Pirozzi, Christopher J ^b   Lopez, Giselle Y ^b   He, Yiping ^b   Friedman, Henry S ^b   Friedman, Allan H ^b   Riggins, Gregory J ^a   Holdhoff, Matthias ^a,d   Burger, Peter ^a   McLendon, Roger E ^b   Bigner, Darell D ^b   Vogelstein, Bert ^a   Meeker, Alan K ^a   Kinzler, Kenneth W ^a   Papadopoulos, Nickolas ^a   Diaz, Luis A ^a,d   Yan, Hai ^b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

ALT; IDH1; IDH2; Mixed gliomas

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; PROTEIN P53;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; ATRX GENE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CIC GENE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FUBP1 GENE; GENE INACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; GLIOMA; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IDH1 GENE; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MOLECULAR PATHOLOGY; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MUTATION; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPIC VARIATION; SEQUENCE ANALYSIS; SOMATIC MUTATION; SURVIVAL TIME; TELOMERE HOMEOSTASIS;

EID: 84868625787     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.588     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007; 114(2):97-109.
2. Wen PY and Kesari S. Malignant glioma in adults (vol 359, pg 492, 2008). New Engl J Med. 2008; 359(8):877-877.
3. Ohgaki H and Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009; 100(12):2235-2241.
4. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-1068.
5. Parsons DW, Jones S, Zhang XS, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, et al. An integrated genomic analysis of human glioblastoma Multiforme. Science. 2008; 321(5897):1807-1812.
6. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, et al. Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110.
7. Phillips HS, Kharbanda S, Chen RH, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG and Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-173.
8. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RGW, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, et al. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell. 2010; 17(5):510-522.
9. Reitman ZJ and Yan H. Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. J Natl Cancer I. 2010; 102(13):932-941.
10. Yan H, Parsons DW, Jin GL, McLendon R, Rasheed BA, Yuan WS, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, et al. IDH1 and IDH2 Mutations in Gliomas. New Engl J Med. 2009; 360(8):765-773.
11. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M and von Deimling A. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta neuropathologica. 2010; 120(6):707-718.
12. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DTW and Collins VP. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology. 2009; 11(4):341-347.
13. Heaphy CM, de Wilde RF, Jiao YC, Klein AP, Edil BH, Shi CJ, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He YP, Yan H, Bigner DD, et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations. Science. 2011; 333(6041):425-425.
14. Schwartzentruber J, Korshunov A, Liu XY, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DAK, Tonjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (vol 482, pg 226, 2012). Nature. 2012; 484(7392):130-130.
15. Eustermann S, Yang JC, Law MJ, Amos R, Chapman LM, Jelinska C, Garrick D, Clynes D, Gibbons RJ, Rhodes D, Higgs DR and Neuhaus D. Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. Nat Struct Mol Biol. 2011; 18(7):777-U750.
16. Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, Allis CD, Picketts DJ, Patel DJ, Li HT and Shi Y. ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. Nat Struct Mol Biol. 2011; 18(7):769-U741.
17. Lewis PW, Elsaesser SJ, Noh KM, Stadler SC and Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. P Natl Acad Sci USA. 2010; 107(32):14075-14080.
18. Watanabe T, Nobusawa S, Kleihues P and Ohgaki H. IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas. Am J Pathol. 2009; 174(4):1149-1153.
19. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JWM, Wesseling P, Reifenberger G, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica. 2009; 118(4):469-474.
20. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre O, Delattre JY and Sanson M. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008; 7.
21. McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS, Robinson BG, Reddel RR and Royds JA. Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. J Neuropath Exp Neur. 2010; 69(7):729-736.
22. Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR and Royds JA. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res. 2006; 66(13):6473-6476.
23. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR and Royds JA. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003; 361(9360):836-838.
24. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih LM, Lacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, et al. Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. Am J Pathol. 2011; 179(4):1608-1615.
25. Cairncross G and Jenkins R. Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma. Cancer J. 2008; 14(6):352-357.
26. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG and Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006; 66(20):9852-9861.
27. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW and Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000; 18(3):636-645.
28. Bettegowda C, Agrawal N, Jiao YC, Sausen M, Wood LD, Hruban RH, Rodriguez FJ, Cahill DP, McLendon R, Riggins G, Velculescu VE, Oba-Shinjo SM, Marie SKN, Vogelstein B, Bigner D, Yan H, et al. Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma. Science. 2011; 333(6048):1453-1455.
29. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An JH, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012; 226(1):7-16.
30. Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A and Hartmann C. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta neuropathologica. 2012; 123(6):853-860.
31. Jiao YC, Shi CJ, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA, Vogelstein B, Kinzler KW, Hruban RH and Papadopoulos N. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors. Science. 2011; 331(6021):1199-1203.
32. Nobusawa S, Watanabe T, Kleihues P and Ohgaki H. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin Cancer Res. 2009; 15(19):6002-6007.
33. Cheung NK, Zhang J, Lu C, Parker M, Bahrami A, Tickoo SK, Heguy A, Pappo AS, Federico S, Dalton J, Cheung IY, Ding L, Fulton R, Wang J, Chen X, Becksfort J, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA: the journal of the American Medical Association. 2012; 307(10):1062-1071.
34. McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BKA, Quinn J, Friedman HS, Friedman AH and Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005; 104(8):1693-1699.
35. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-U137.
36. Kim YH, Lachuer J, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nobusawa S, Nakazato Y, Tanaka Y, Vital A, Mariani L and Ohgaki H. Alterations in the RB1 Pathway in Low-grade Diffuse Gliomas Lacking Common Genetic Alterations. Brain Pathol. 2011; 21(6):645-651.
37. Figarella-Branger D, de Paula AM, Colin C and Bouvier C. Histomolecular classification of adult diffuse gliomas: The diagnostic value of immunohistochemical markers. Rev Neurol-France. 2011; 167(10):683-690.
38. Holdhoff M and Grossman SA. Controversies in the Adjuvant Therapy of High-Grade Gliomas. Oncologist. 2011; 16(3):351-358.
39. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-274.
40. Meeker AK, Gage WR, Hicks JL, Simon I, Coffman JR, Platz EA, March GE and De Marzo AM. Telomere length assessment in human archival tissues - Combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol. 2002; 160(4):1259-1268.
41. Koorstra JBM, Hong SM, Shi CJ, Meeker AK, Ryu JK, Offerhaus GJA, Goggins MG, Hruban RH and Maitra A. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Modern Pathol. 2009; 22(11):1439-1445.
42. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, Schild L, Molenaar P, Stroeken P, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483(7391):589-U107.